Trial · NCT02057250
Participant flow35
How many started, completed or left each group, period by period.
1 to 20 of 35
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| AID Assessment Phase | STARTED | Sarilumab 150 mg by AID (AID Assessment Phase) | 56 | |
| AID Assessment Phase | STARTED | Sarilumab 150 mg by PFS (AID Assessment Phase) | 53 | |
| AID Assessment Phase | STARTED | Sarilumab 200 mg by AID (AID Assessment Phase) | 52 | |
| AID Assessment Phase | STARTED | Sarilumab 200 mg by PFS (AID Assessment Phase) | 56 | |
| AID Assessment Phase | STARTED | Sarilumab 150 mg by PFS (Extension Phase) | 0 | |
| AID Assessment Phase | COMPLETED | Sarilumab 150 mg by AID (AID Assessment Phase) | 52 | |
| AID Assessment Phase | COMPLETED | Sarilumab 150 mg by PFS (AID Assessment Phase) | 50 | |
| AID Assessment Phase | COMPLETED | Sarilumab 200 mg by AID (AID Assessment Phase) | 45 | |
| AID Assessment Phase | COMPLETED | Sarilumab 200 mg by PFS (AID Assessment Phase) | 54 | |
| AID Assessment Phase | COMPLETED | Sarilumab 150 mg by PFS (Extension Phase) | 0 | |
| AID Assessment Phase | NOT COMPLETED | Sarilumab 150 mg by AID (AID Assessment Phase) | 4 | |
| AID Assessment Phase | NOT COMPLETED | Sarilumab 150 mg by PFS (AID Assessment Phase) | 3 | |
| AID Assessment Phase | NOT COMPLETED | Sarilumab 200 mg by AID (AID Assessment Phase) | 7 | |
| AID Assessment Phase | NOT COMPLETED | Sarilumab 200 mg by PFS (AID Assessment Phase) | 2 | |
| AID Assessment Phase | NOT COMPLETED | Sarilumab 150 mg by PFS (Extension Phase) | 0 | |
| Extension Phase | STARTED | Sarilumab 150 mg by AID (AID Assessment Phase) | 0 | |
| Extension Phase | STARTED | Sarilumab 150 mg by PFS (AID Assessment Phase) | 0 | |
| Extension Phase | STARTED | Sarilumab 200 mg by AID (AID Assessment Phase) | 0 | |
| Extension Phase | STARTED | Sarilumab 200 mg by PFS (AID Assessment Phase) | 0 | |
| Extension Phase | STARTED | Sarilumab 150 mg by PFS (Extension Phase) | 192 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02057250/flow